Shilpa Medicare shares jumped more than 3% after its CDMO customer received Fast Track Designation from the US FDA for their investigational drug for Glioblastomaa (GBM).
SML offers end-to-end solutions for API and formulation development. This is the second CDMO contract in which the partner has obtained Fast Track Designation, demonstrating Shilpa’s ability to produce challenging molecules. SML is presently the only partner working on the project.
As of 2:50 pm, Shilpa Medicare shares were trading 1.76% higher at Rs 901.35 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
